High-dose thiotepa-related neurotoxicity and the role of tramadol in children

[1]  K. Jahnukainen,et al.  Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma , 2012, Pediatric blood & cancer.

[2]  Ann M. Philbrick,et al.  Avoiding Serotonin Syndrome: The Nature of the Interaction Between Tramadol and Selective Serotonin Reuptake Inhibitors , 2012, The Annals of pharmacotherapy.

[3]  G. Bigelow,et al.  Discriminative Stimulus Effects of Tramadol in Humans , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  Carmine Zoccali,et al.  Selection Bias and Information Bias in Clinical Research , 2010, Nephron Clinical Practice.

[5]  R. Sansone,et al.  Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. , 2009, Psychiatry (Edgmont (Pa. : Township)).

[6]  Jos H Beijnen,et al.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. , 2009, British journal of clinical pharmacology.

[7]  Audrea H Szabatura,et al.  Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant , 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[8]  S. Rodenhuis,et al.  Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency , 2008, Cancer Chemotherapy and Pharmacology.

[9]  D. Frappaz,et al.  High‐dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy , 2007, Cancer.

[10]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[11]  P. Charbonneau,et al.  Refractory shock and asystole related to tramadol overdose , 2007, Clinical toxicology.

[12]  A. Santoro,et al.  High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. , 2007, Current stem cell research & therapy.

[13]  Z. Martinovic,et al.  Seizures Associated with Intoxication and Abuse of Tramadol , 2006, Clinical toxicology.

[14]  M. Dewhirst,et al.  The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. , 2005, AJR. American journal of roentgenology.

[15]  S. Rodenhuis,et al.  Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism , 2005, Cancer Chemotherapy and Pharmacology.

[16]  M. Eichelbaum,et al.  Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based. , 2005, Biochemical pharmacology.

[17]  H. Pihko,et al.  High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: A case report , 1990, Journal of Neuro-Oncology.

[18]  S. Grond,et al.  Clinical Pharmacology of Tramadol , 2004, Clinical pharmacokinetics.

[19]  M. Dimopoulos,et al.  Dosing of thioTEPA for myeloablative therapy , 2004, Cancer Chemotherapy and Pharmacology.

[20]  D. Orbach,et al.  Toxicit neurologique centrale des chimiothrapies : tat des connaissances actuelles , 2003 .

[21]  H. Brisse,et al.  [Central neurological manifestations during chemotherapy in children]. , 2003, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[22]  A. Birnbaum,et al.  Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA , 2002, Cancer Chemotherapy and Pharmacology.

[23]  S. Rodenhuis,et al.  Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  S. Rodenhuis,et al.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. , 2001, British journal of clinical pharmacology.

[25]  M. Ripple,et al.  Lethal combination of tramadol and multiple drugs affecting serotonin. , 2000, The American journal of forensic medicine and pathology.

[26]  B. Bégaud.  [Criteria of imputability in accidents of drug-induced origin]. , 2000, La Revue du praticien.

[27]  J. Beijnen,et al.  Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA). , 2000, Cancer treatment reviews.

[28]  S. Rodenhuis,et al.  The clinical pharmacology of alkylating agents in high-dose chemotherapy. , 2000, Anti-cancer drugs.

[29]  O. Oberlin,et al.  Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors , 1998, Bone Marrow Transplantation.

[30]  M. Fukuzawa,et al.  Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors , 1998, Bone Marrow Transplantation.

[31]  R. Packer,et al.  Acute neurologic dysfunction associated with high-dose chemotherapy and autologous bone marrow rescue for primary malignant brain tumors. , 1997, Pediatric neurosurgery.

[32]  T. Philip,et al.  Autologous stem cell transplantation for solid tumors in children , 1997, Current opinion in pediatrics.

[33]  R. Zimmerman,et al.  Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Deangelis,et al.  Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients , 1996, Neurology.

[35]  P. van Bladeren,et al.  The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. , 1995, Cancer research.

[36]  D. Valteau‐Couanet,et al.  Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Steinberg,et al.  A phase II evaluation of thiotepa in pediatric central nervous system malignancies , 1993, Cancer.

[38]  G. Vassal,et al.  High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. , 1992, Bone marrow transplantation.

[39]  A. Mäkipernaa,et al.  High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. , 1991, Bone marrow transplantation.

[40]  C. Begg,et al.  High-dose thiotepa alone and in combination regimens with bone marrow support. , 1990, Seminars in oncology.

[41]  J. Fay,et al.  High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. , 1990, Seminars in oncology.

[42]  B. Teicher,et al.  Preclinical studies and clinical correlation of the effect of alkylating dose. , 1988, Cancer research.

[43]  M. Egorin,et al.  Cellular pharmacology of N,N',N''-triethylene thiophosphoramide. , 1988, Cancer letters.

[44]  T. Spitzer,et al.  High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. , 1987, Cancer treatment reports.

[45]  M. Egorin,et al.  Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. , 1986, Cancer treatment reports.

[46]  R. Kaplan,et al.  Neurotoxicity of antineoplastic drugs. , 1982, Seminars in oncology.

[47]  G. Schwartz,et al.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine , 2004 .

[48]  H. Weiss,et al.  Neurotoxicity of commonly used antineoplastic agents (first of two parts). , 1974, The New England journal of medicine.